Investment
Features
FeesSafety
Academy
More
Pluang+

Compare MasterCard Inc (MA) vs Twist Bioscience Corp (TWST) Price & Performance

MasterCard IncTrade
Twist Bioscience CorpTrade

Price performance (Past 24H)

Key statistics

MasterCard Inc vs Twist Bioscience Corp — how do they compare? MasterCard Inc trades at $561.9 (market cap $493.34B), while Twist Bioscience Corp trades at $123.01 (market cap $7.82B). The key difference: MasterCard Inc is far larger — about 63.1× Twist Bioscience Corp's market cap, and MasterCard Inc pays a 0.62% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.

MATWST
Market Cap
$493.34B$7.82B
Volume
4,635,698
Sector
Consumer CyclicalHealth
52-Week High
$598.96$124.88
52-Week Low
$471.55$24.16
Enterprise Value
$506.38B$7.75B
Dividend Yield
0.62%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

MasterCard Inc

Mastercard (MA) trades at $563.17, up 0.04% on the day, with a bullish technical signal supported by moving averages and strong institutional buying interest. The company continues to deliver robust financial performance, with Q2 2026 EPS of $5.04 beating estimates of $4.77, marking the third consecutive quarterly beat. Revenue growth remains strong, rising from $22.2B in 2022 to $32.8B in 2025, while maintaining net income margins above 45%. Recent news highlights Mastercard's expansion into AI-driven payments and initiatives to connect underbanked populations.

The outlook for MA remains positive given its consistent earnings beats, high profitability, and dominant market position. However, investors should monitor competitive threats from emerging payment technologies like stablecoins and regulatory scrutiny. With 79% analyst buy ratings and a consensus price target of $660.85, Wall Street sees approximately 17% upside potential from current levels.

Twist Bioscience Corp

Twist Bioscience (TWST) trades at $115.67, up 6.04% in the last session, with bullish technical signals from moving averages and a recent analyst upgrade. Revenue growth is strong, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, though the company remains unprofitable with negative net income margins. A recent $300 million public offering at $96 per share indicates capital raising for expansion.

The outlook is mixed: robust revenue growth and high analyst buy ratings (78.57%) support upside potential, but persistent losses, cash burn, and high valuation ratios pose significant risks. Investors should weigh growth prospects against financial sustainability concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About MasterCard Inc

Mastercard Incorporated provides financial transaction processing services. The Company offers payment processing services for credit and debit cards, electronic cash, automated teller machines, and travelers checks. Mastercard serves customers worldwide.

Read more on MA

About Twist Bioscience Corp

Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.

Read more on TWST